trending Market Intelligence /marketintelligence/en/news-insights/trending/72fyehj_icltBYOirKzn7g2 content esgSubNav
In This List

AbbVie brain cancer drug fails to improve survival in phase 3 study

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


AbbVie brain cancer drug fails to improve survival in phase 3 study

AbbVie Inc. said its medicine Depatux-M failed to improve survival in patients with brain cancer when used as an add-on, in a late-stage study called Intellance-1 — prompting an independent data monitoring committee to recommend that it be stopped instead.

The North Chicago, Ill.-based biotechnology giant was evaluating Depatux-M against placebo in the phase 3 trial to treat newly diagnosed glioblastoma with the epidermal growth factor receptor gene mutation.

Glioblastoma is the most aggressive form of brain cancer.

AbbVie said an interim analysis based on data from 639 patients showed that the trial did not meet its primary goal of improving overall survival. The company has halted enrollment in all ongoing Depatux-M studies as a result.

AbbVie said it will submit results from the study, which was conducted in collaboration with the RTOG Foundation, at a medical conference.